Susan Apkon
Pediatric Rehabilitation Medicine · Aurora, CONPI 1083707434
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $7,980 of the $10,916 with a category attached, or 73.1%. Sarepta Therapeutics, Inc. accounts for 63.6% of it on its own, with 6 other manufacturers making up the rest. Reporting peaked in 2020 at $6,725 and has fallen 76.2% since, to $1,601 in 2025.
Across 24 payments — averaging $454.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sarepta Therapeutics, Inc.$7K
- Biogen$2K
- ITF Therapeutics LLC$2K
- Vertex$500
- PTC Therapeutics, Inc.$91
- AbbVie$24
- plus $13 from 1 others
Across 230 payments — averaging $4076.56 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Sarepta Therapeutics, Inc.$847K
- Pfizer$84K
- PTC Therapeutics, Inc.$7K
- Biogen$176
What the payments were for
- Consulting fees$7,98073%
- Speaking & faculty fees$1,32512%
- Travel & lodging$9839%
- Food & beverage$4634%
- Education$1652%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sarepta Therapeutics, Inc. | 13 | $6,946 |
| Biogen | 2 | $1,741 |
| ITF Therapeutics LLC | 4 | $1,601 |
| Vertex | 1 | $500 |
| PTC Therapeutics, Inc. | 2 | $91 |
| AbbVie | 1 | $24 |
| Catalyst Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Exondys 51$6,604
- SPINRAZA$1,680
How this compares
Too few pediatric rehabilitation medicine providers in Coloradoto place this figure against a meaningful peer group, so we don't.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Exondys-51Eteplirsen | 16 | $1,131,520 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Sarepta Therapeutics, Inc.Exondys-51 | $6,946 | $1,131,52016 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few pediatric rehabilitation medicine providers in Coloradoon file to place this against a meaningful peer group, so we don't.
Other pediatric rehabilitation medicine in Aurora
- Joyce OleszekAurora$9K
- Anne StrattonAurora$6K
- Aaron PowellAurora$135
- Stephanie TowAurora$84
- Jordan WyrwaAurora$77
- Amy KanallakanAurora$60
- Matthew MayerAurora$20
- Pamela WilsonAurora$0
- Suzanne RosenbergDenver$991
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.